'Inadvertent Reversal' of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA - TCTMD

'Inadvertent Reversal' of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA  TCTMD

(UPDATED) A serious error in data reporting in the Zilver PTX trial reverses the conclusion that there was a long-term mortality advantage for the ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more